SAMPLE PREP 2015 - 样品制备技术学会 2015 -
2015年6月25 - 26日
美国,马里兰州,贝塞斯达

分析前/检测前处理的优化,应该紧密跟随或甚至优先于新体学分析的兴起。创新样品制备与标的浓缩技术对于异体样品或是包含低浓度检体的样品来说,具有大幅提升检验的敏感性与特异性的能力。适当且新式的样品制备,对于确保重复性与强健性的分析平台与确效来说,为极为重要的一个部分。本会议将针对在临床、生物检测以及生物监测领域,因应最新体学分析的样品制备相关主要课题与最新进展进行交流讨论。


第1天 | 第2天

6月25日(四)

7:15 报到登记与晨间咖啡


基因检测与病原体检测之分析前处理最佳实务

8:10 议长开会致词

8:15 生物检体的生物质量评价

Scott-JewellScott D. Jewell, Ph.D., Professor and Director, Program for Technologies and Cores Van Andel Research Institute

Biospecimen quality is affected by preanalytical variable and the analytes from the biospecimen are the targets of that quality assessment. Purity, size, integrity and a functional assessment of nucleic acids are used to measure genomic biospecimen quality. However, a more complex measurement of quality is the assessment of the biology of the biospecimen. We investigate these questions using animal models to provide further improvements in best practices.

8:45 共同简报:做为创新且高度集成的分子系统核心特徵的样品制备

Randy-RasmussenRandy Rasmussen, Ph.D., President and COO, BioFire Diagnostics

Stephanie Thatcher, Ph.D., Director, Systems Integration, BioFire Diagnostics

Development of molecular detection systems focuses on nucleic acid amplification and detection. This half of the problem gets the grants, the patents and the research time. Unfortunately these systems are often brought to their knees by snot, blood, poop and sputum. The hardest part of highly integrated systems is the sample prep and yet it is the part that is hardest to get people to work on. We will describe the process of learning this lesson with the FilmArray system, how we approach sample prep, and what important factors you should consider during development.

9:30 直接全血检体的细菌感染及念珠菌感染的敏感分子检测

Lawrence-BlynLawrence B. Blyn, Ph.D., Director, Science and Technology, Ibis Biosciences, Abbott

We describe a sample preparation and detection system that provides for the rapid detection and identification of bacterial and Candidal nucleic acid directly in whole blood specimens from patients with suspected bloodstream infections. A lysis method and DNA purification system were designed for processing 5 ml of whole blood. PCR amplification formulations were optimized for high levels of human DNA. The system provides for rapid and sensitive molecular detection of diverse agents of these clinically important infections in approximately 6h.

10:00 展示会场休息与论文海报鉴赏

10:45 使用次世代定序分析以比较从合适福马林固定组织及冰冻组织检体所获得的结果

Patrick-HurbanPatrick Hurban, Ph.D., Vice President, Research and Development, Expression Analysis, The Quintiles Company

Formalin-fixed tissues present many sample preparation, extraction and method development challenges. It can also be challenging to understand whether certain findings stem from intrinsic genetic properties of the sample, or alternatively, are a product of how the sample was handled. Despite advancements in preservation methods, vast collections of FFPE material await analysis. Results will be presented comparing matched formalin-fixed and frozen tumor samples analyzed using a sensitive next-generation sequencing assay.

11:15 标靶RNA定序的融合检测最佳实务:分析前考量事项、分析确效等

Robert-DaberRobert D. Daber, Ph.D., Director, Research and Development and Sequencing Operations, Bio-Reference Laboratories

This presentation will discuss challenges and benefits of NGS based targeted RNA sequencing in the detection of gene fusion events, including, nucleic acid isolation, sample preparation and downstream data processing. There are a number of specific challenges related to RNA sequencing, standardized quality control metrics both before and after library prep are clearly needed.

11:45 赞助商简报发表

12:15 午餐会简报发表或是自行享用午餐

1:00 展示会场休息与论文海报鉴赏

1:40 议长致词

1:45 癌症临床研究使用的多重检体NGS分析的准备

Mickey-WilliamsP. Mickey Williams, Ph.D., Director, Molecular Characterization & Clinical Assay Development Laboratory (MoCha), Frederick National Laboratory for Cancer Research

NGS offers a powerful tool for assessment of molecular defects found in cancer. The utilization of NGS is becoming common practice in clinical laboratories. This complex technology requires a new level of analytical performance testing and validation. This discussion will focus on approaches used for analytical validation of the NGS clinical assay used for treatment selection in the NCI-MPACT Study.

2:15 部分临床样品的多重标的定序

Curt-ScharfeCurt Scharfe, M.D., Ph.D., Senior Scientist, Stanford Genome Technology Center, Stanford University

Clinical molecular testing increasingly depends on the development and deployment of novel sample preparation technologies. In collaboration with physicians and clinical laboratories we are developing genomic and sequencing assays for the screening and diagnosis of cystic fibrosis, clinical viral infections, newborn and neurodevelopmental conditions and inherited cardiomyopathies. These projects have involved invention of a novel multiplex capture technology, and several innovative improvements in DNA sample preparation. Both approaches have increased speed and accuracy, while lowering costs.

2:45 展示会场休息与论文海报鉴赏

3:15 透过DeepChek&OncoChek平台的病毒学及肿瘤学的样品制备与分析确效的优化

Chalom-SayadaChalom Sayada, M.D., Ph.D., Co-founder & CEO, Advanced Biological Laboratories SA

Clinical environments wishing to provide genotyping services in the field of Virology or Human Genetics using Next Generation Sequencing (NGS) need robust, standardized, registered and well-validated software systems. These should be tailored to the optimized management of genomic data resulting in personalized healthcare. Dedicated downstream analysis systems help to perform an accurate, quick and simple analysis of NGS data. This begins with sample preparation and the generation of reads by any type of sequencing platform and ends with simple and easily-understandable reporting ideally suited to clinical interpretation and the connection to the local LIMS. Coupling advanced IT solutions to a well-established sequencing workflow usually helps labs with the validation of new sample prep and innovative assays, enhancing patient management.

3:45 赞助商简报发表


4:15 座谈会:核酸萃取法与分析目标的配合

Moderator:
Patrick-HurbanPatrick Hurban, Ph.D., Vice President, Research and Development, Expression Analysis, The Quintiles Company





Panelists: Speakers of the Day


4:45 专题研讨会报到登记

5:30-8:30 晚餐专题研讨会(需要另外报名登记。)



第1天 | 第2天

6月26日(五)

8:00 晨间咖啡


多重分析:样品制备与确效

8:25 议长致词

8:30 切合目的的生物检体采样与使用规范的National Cancer Institute资源

Helen-MooreHelen Moore, Ph.D., Branch Chief, Biorepositories & Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

The National Cancer Institute has led the way in developing Best Practices for Biospecimen Resources, sponsoring new research in Biospecimen Science, and building groundbreaking research biospecimen collections including postmortem biospecimens for the NIH GTEx program. New projects to build evidence-based best practices for frozen and FFPE tissues will be described.

9:00 针对NGS成功的FFPE样品评价

Helen-FernandesHelen Fernandes, Ph.D., Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medical College

This presentation will discuss several important issues, such as: RNA detection in cancer tissues stored in FFPE samples, profiling microRNA expression, FFPE DNA quality control and its correlation with NGS data, and understanding pre-analytic effects on RNA gene expression.

9:30 赞助商简报发表

10:00 休息时间


因应各种适应症的分析前考量事项

10:15 从血液检体直接采样的活菌快速样品制备

Alexis-Sauer-BudgeAlexis Sauer-Budge, Ph.D., Senior Research Scientist, Fraunhofer Center for Manufacturing Innovation; Adjunct Research Assistant Professor, Biomedical Engineering, Boston University

Traditionally, bacterial pathogens in the blodd have been identified using culture-based methods that can take several days to obtain results. This can lead to physicians making treatment decisions based on an incomplete diagnosis contributing to patient morbidity. To decrease diagnosis time, we are developing a novel sample preparation device for isolating and concentrating dilute bacteria from blood. This presentation will describe the sample preparation device for methodology to isolate viable bacteria from blood which is clean enough for direct PCR or other downstream detection technologies.

10:45 细菌隔离与可携式检测:分析前考量事项与技术

Sam-NugenSam R. Nugen, Ph.D., Assistant Professor, Department of Food Science, University of Massachusetts, Amherst

The lack of a practical method for bacterial separation remains a hindrance for the low-cost and successful development of rapid detection methods from complex samples. We have developed T7 bacteriophage magnetic probes, where T7 bacteriophage is bound to magnetic particles. The capture efficiencies of bacteriophages on microbeads and nanoparticles for the separation of E. coli K12 were determined. The results indicated that bacteriophage magnetic particles achieved a capture efficiency of 93.7 篑 1.1% in 15 minutes.

11:15 GAA次世代定序的微流体PCR扩增以检测造成庞贝氏症的突变原因

Patricia Mueller, Ph.D., Chief, Molecular Risk Assessment Laboratory, Newborn Screening and Molecular Biology Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention (CDC)

We designed a next-generation sequencing assay using primer pairs for PCR amplification and library preparation of up to 48 samples in one Fluidigm Access Array for next-generation sequencing using the MiSeq. This assay can be scaled up using additional Access Arrays in one MiSeq run. The PCR amplification of GAA is challenging due to difficult regions in the gene. All transcribed exon sequences as well as exon/intron borders including those intron sequences containing mutations as identified in the Human Genome Mutation Database (HGMD) were targeted for amplification. Primers were designed not to overlap known HGMD mutations, and variants found in dbSNP were avoided when possible. The data was filtered at a quality score of ??30 and trimmed. We characterized reference materials including those with missense, nonsense, and splicing mutations; and small insertions and deletions. Large deletions that included exon 18 were independently characterized.

11:45 分析前变量-生物标记确效上最脆弱且未受到充分评价的阶段

Apurva K. Srivastava, Ph.D., Principal Scientist, Frederick National Laboratory for Cancer Research Leidos Biomedical Research, Inc.

Contrary to prevalent belief, pre-analytic factors contribute to the most errors documented in clinical laboratories as compared to analytical factors where most efforts are devoted during assay validation. Dr. Srivastava will discuss the general pre-analytical variables for protein assays and how they affect accuracy in clinical laboratory tests. The focus of his presentation will be on identifying the phases of pre-analytical factors with reference to pharmacodynamic/proof-of-mechanism (POM) phospho-protein biomarkers in clinical trials. As a take home message, participants will learn that pre-analytic variables are an underappreciated area in biomarker validation process and improvements in this process will significantly impact accuracy of test results and enable laboratories to focus their quality assurance efforts.

12:15 学会结束


第1天 | 第2天


* 活动内容有可能不事先告知作更动及调整。

 

Choose your language
Chinese
Japanese
Korean
English


Catalog


产业会议汇总历
医疗设备相关国际会议

医疗设备相关国际会议

免费电子邮件通知服务
免费电子邮件通知服务